Last reviewed 2026-04-20 · How we verify

Estocin (DIMENOXADOL)

Phase 2 active Small molecule

Estocin (generic name: DIMENOXADOL) is a dimenoxadol drug. It is currently in Phase 2 development.

Estocin works by modulating the activity of certain neurotransmitters in the brain.

Estocin, also known as Dimenoxadol, is a small molecule drug in the dimenoxadol class. Its exact target is unknown, but it is believed to work by modulating the activity of certain neurotransmitters in the brain. Estocin is not FDA-approved for any indications, and its commercial status is unclear. As a result, there is limited information available on its safety profile and potential side effects. Further research is needed to fully understand the properties and potential uses of Estocin.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIMENOXADOL
Drug class	dimenoxadol
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Estocin helps regulate the way these messengers work, which can affect how we feel pain and other sensations. By fine-tuning this process, Estocin may help reduce pain and discomfort.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Estocin CI brief — competitive landscape report
Estocin updates RSS · CI watch RSS

Frequently asked questions about Estocin

What is Estocin?

Estocin (DIMENOXADOL) is a dimenoxadol drug.

How does Estocin work?

Estocin works by modulating the activity of certain neurotransmitters in the brain.

What is the generic name of Estocin?

DIMENOXADOL is the generic (nonproprietary) name of Estocin.

What drug class is Estocin in?

Estocin belongs to the dimenoxadol class. See all dimenoxadol drugs at /class/dimenoxadol.

What development phase is Estocin in?

Estocin is in Phase 2.

Drug class: All dimenoxadol drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing